List view / Grid view
The first-in-human clinical trial of nanoformed piroxicam will begin in…
The first-in-human clinical trial of nanoformed piroxicam will begin in late 2020, with results expected by mid-2021.
Quotient Clinical, the Translational Pharmaceutics® Company, and Sunesis Pharmaceuticals have…
21 January 2015 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics® Company, and Sunesis Pharmaceuticals have announced the initiation of a clinical mass balance/ADME trial for vosaroxin – a candidate therapeutic for acute myelogenous leukemia (AML)...
Quotient Clinical has announced the extension of its Translational Pharmaceutics™…
7 May 2014 | By kdm communications
Quotient Clinical has announced the extension of its Translational Pharmaceutics™ platform into patient-focused cancer drug development...
Quotient Clinical has commenced its 50th RapidFACT (Rapid Formulation development…
7 February 2014 | By kdm communications
Quotient Clinical has commenced its 50th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the development of this service...
Quotient Clinical has been acquired from the Quotient Bioresearch Group…
11 December 2013 | By KDM Communications
Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital for an undisclosed sum...
To accommodate demand for its RapidFACT Service...
3 March 2011 | By The Scott Partnership
To accommodate demand for its RapidFACT Service...
Speeding the advance of compounds to clinical trials and expanding…
10 November 2010 | By The Scott Partnership
Speeding the advance of compounds to clinical trials and expanding options for drug delivery...
Quotient Bioresearch, will be highlighting integrated early stage drug development…
12 October 2010 | By The Scott Partnership
Quotient Bioresearch, will be highlighting integrated early stage drug development platforms at FIP Pharmaceutical Sciences World Congress...
